IL2 and acute myeloid leukemia: A similar strategy was done to avoid stimulation of Tregs that are produced due to administration of IL-2 along with haploidentical NK cell infusion in refractory AML patients which was to take intravenous (IV) or subcutaneous (SC) recombinant human IL-15 (rhIL-15) [16].